e-Lung CT Biomarkers Can Stratify Patients at Risk of IPF Progression at 52 Weeks; Post-hoc Analysis From a Randomised Control Trial

e-Lung WRVS CT biomarker accurately predicted which patients were at risk of 52-week FVC decline. These data suggest that the e-Lung WRVS tool may allow enrichment of clinical trials for progressive patients, identify patients at low risk of IPF progression, and facilitate well-matched treatment arms. Further work is ongoing to validate these findings in additional cohorts.